Policy / Pricing Most patients “won’t see benefit” with Alzheimer’s drugs PharmaphorumA review of clinical data on amyloid-targeting Alzheimer's therapies has found absent or trivial efficacy, but is facing pushback from some experts.Policy / PricingNeuroscienceRead full story pharminent April 16, 2026 (Last updated: April 16, 2026) Pharmaphorum A review of clinical data on amyloid-targeting Alzheimer’s therapies has found absent or trivial efficacy, but is facing pushback from some experts. Policy / PricingNeuroscienceRead full story Post navigation Previous: Terremoto wins $108m in Series C to drive cancer and rare disease programmesNext: Beeline raises $300m for BMS drugs, and other biofinancings Related Stories Policy / Pricing MFN affecting Swiss medicines access, says Interpharma pharminent August 13, 2026 Policy / Pricing Prior Authorization Metrics Provide New Insights into Insurer Practices, but Gaps Remain pharminent August 13, 2026 Policy / Pricing Trump signs order that nearly halves childhood immunisation coverage pharminent August 11, 2026
